Quaternary salts of tri-(beta-propyloxyethyl)amine derivatives and process for producing same

ABSTRACT

NOVEL QUATERNARY SALTS OF TRI-(B-PROPYLOXYETHYL) AMINE DERIVATIVES OF THE FORMULA:   R-N+-(CH2CH2OCH2CH2CH3)3X-   WHEREIN R IS A MEMBER SELECTED FROM THE GROUP CONSISTING OF ALKYL GROUPS; ARALKYL GROUPS EXCEPT BENZYL GROUP; CYCLOHEXYLALKYL GROUPS; BENZYL GROUPS SUBSTITUTED BY HYDROXYL, ALKOXY, PHENOXY OR BENZYLOXY GROUP; BENZYL GROUPS SUBSTITUTED BY AT LEAST TWO LOWER ALKYL GROUPS; CINNAMYL GROUP; A PHENACYL GROUP; PHENOXYALKYL GROUPS; AND NAPHTHYLMETHYL GROUP; AND X STANDS FOR A HALOGEN ATOM AND A PROCESS FOR THE PREPARATION OF QUATERNARY SALTS OF TRI-(B-PROPYLOXYETHYL) AMINE DERIVATIVES OF THE ABOVE FORMULA (I) BY REACTING TRI(B-PROPYLOXYETHYL) AMINE OF THE FORMULA   N-(CH2CH2OCH2CH2CH3)3   WITH A COMPOUND OF THE FORMULA   RX   WHEREIN R AND X ARE AS DEFINED ABOVE THE COMPOUNDS POSSESS ANTI-ULCER PROPERTIES.

U nitecl States Patent Oflice 3,819,705 Patented June 25, 1974 US. Cl. 260567.6 M 1 Claim ABSTRACT OF THE DISCLOSURE Novel quaternary salts of tri-(fl-propyloxyethyl) amine derivatives of the formula:

wherein R is a member selected from the group consisting of alkyl groups; aralkyl groups except benzyl group; cyclohexylalkyl groups; benzyl groups substituted by hydroxyl, alkoxy, phenoxy or benzyloxy group; benzyl groups substituted by at least two lower alkyl groups; cinnamyl group; a phenacyl group; phenoxyalkyl groups; and naphthylmethyl group; and X stands for a halogen atom and a process for the preparation of quaternary salts of tri-(,S-propyloxyethyl) amine derivatives of the above formula (I) by reacting tri(}8-propyloxyethyl) amine of the formula N-(CH 'CH OCH CH CH (II) with a compound of the formula RX (III) wherein R and X are as defined above the compounds possess anti-ulcer properties.

This invention relates to novel quaternary salts of tri- (B-propyloxyethyl) amine derivatives, pharmaceutical compositions comprising them and a process for the preparation of said novel quaternary salts.

More specifically, the invention relates to quaternary salts of tri-(B-propyloxyethyl) amine derivatives expressed by the formula:

wherein R is a member selected from the group consisting of alkyl groups; aralkyl groups except benzyl group; cyclohexylalkyl groups; benzyl groups substituted by hydroxyl, alkoxy, phenoxy or benzyloxy group; benzyl groups substituted by at least two lower alkyl groups; cinnamyl group; a phenacyl group; phenoxyalkyl groups; and naphthylmethyl groups; and X stands for a halogen atom.

This invention further relates to a process for the preparation of quaternary salts of tri (,9 propyloxyethyl) amine derivatives of the above formula (I) which comprises reacting tri-(p-propyloxyethyl) amine of the formula 3 with a compound of the formula wherein R and X are as defined above.

In the definition of R in the above formula (I), the alkyl groups include straight or branched saturated hydrocarbon radicals having 1-10 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, pentyl, heptyl and decyl groups. By the term aralkyl groups except benzyl group are meant hydrocarbon radicals expressed by the formula in which n is an integer of 2 to 5, such as phenethyl and phenylpentyl group. The cyclohexylalkyl groups designate hydrocarbon radicals expressed by the formula in which n is an integer of 1 to 5, such as cyclohexylmethyl and cyclohexylpentyl groups. The benzyl groups substituted by hydroxyl group includes benzyl groups which are substituted by hydroxyl groups in the 0-, mor p-position. The benzyl groups substituted by alkoxy group include benzyl groups which have as a substituent a lower alkoxy group such as methoxy, ethoxy or propyloxy in the 0-, mor p-position. The benzyl groups substituted by benzyloxy (group) include benzyl groups which are substituted by benzyloxy group in the 0-, mor p-position. As the benzyl groups substituted by at least two lower alkyl groups there may be exemplified 3,5-dimethylbenzyl, 2,3,5-trimethylbenzyl, 3,4,5-trimethylbenzyl and 3,5-diethylbenzyl groups. The phenoxyalkyl groups include hydrocarbon radicals expressed by the formula in which n is an integer of 2 to 5, such as phenoxyethyl and phenoxypentyl groups.

It has been known in the art that benzyl-tri-(fi-propyloxyethyl) ammonium iodide, which has a similar structure to those of compounds of this invention, exhibits a preventive effect against the development of gastric ulcer. Although this known compound is meritorious in that it exhibits hardly any anti-cholinergic elfect and does not cause such side-effects as constipation and dryness of mouth, its anti-ulcer activity is still insufiicient.

The primary object of this invention is to provide useful anti-ulcerative compounds, pharmaceutical compositions containing them and a process for the preparation thereof.

Excellent medicinal properties of the novel compounds of the invention will be readily understood from the results of animal experiments which are detailed hereinbelow.

Samples Tested Para-phenoxybenzyl-tri- (/8-propyloxyethyl) ammonium bromide was selected as a typical compound of this invention and its effect as an anti-ulcer agent was evaluated by the method described below. As a comparative sample there was chosen benzyl-tri-(fl-propyloxyethyl) ammonium bromide which is included in compounds disclosed in the specification of British Pat. No. 1,025,160. The former compound is designated as Compound A and the latter compound is designated as Compound B.

Preparation of Test Solutions Since both the Compound A and Compound B are insoluble in water, each of them was dissolved in an amount of 5 mg. into 1 ml. of 5% aqueous ethanol.

Method Procedure: The test was carried out by the method of H. Shay et a1. [Gastroenterology, vol. 5, page 43 (1945)]. Thus, after male rats of Wister strain having a body weight of -180 g. were fastened for 48 hours, their pylori were ligated. Just after the above procedure, the test solution was subcutaneously administered. After fasting for a further period of 18 hours, abdomina of the rats were cut again under chloroform anesthesia, and their stomachs were removed.

Observation of Ulcer Under stereoscopic microscope, there were observed the degree of ulcer and the mocosa of the stomach.

Test on Gastric Juice The pepsin activity was estimated with the method or Bonfils S. M. Durrasquet et al. [Rev. Fronce et Udes Clin et Bil, vol. 5, page 71 (1960)].

Thus, the gastric juice was diluted to 20 times with an aqueous HCl solution (to pH 1.6). Then, 2.0 ml. of the diluted solution and 1.0 ml. of 3% solution of dried human plasma whose pH was adjusted to 1.6 were mixed,

and incubated exactly at 37 C., for 30 minutes. The

amount of tyrosine formed by decomposition of the human plasma was measured at 275 mg with a Spectrophotometer. The pepsin activity was expressed in terms of the amount of tyrosine formed.

Results Results of the above tests are shown in Tables 1 and 2.

TABLE 1 EtIccts of Compound A and Compound B an ulcer development in pylorus ligated rats (subcutaneous administration) Number oi- Dose Rats Dead No ulcer (mg/kg.) tested rats Rupture rats Compound:

X In control I, rats which underwent ligation of pylorus and subcutaneous injection of 0.2 ml./100 g. of 5% alcohol were tested.

t th:i control II, rats which underwent only ligation of pylorus were es e *The column rupture" indicates the number of rats in which the contents of the stomach were scattered intraperitoneal because of rupture on the ulcerated portion but which were still alive.

"The value of the denominator in the column indicates the number of rats that survived and the value of the numerator indicates the number of rats on whose stomach no ulcer was developed.

TABLE 2 Test on Gastric Juice Secretion Inhibiting Activity in Gastric Mucosa of Frog and Test on Anti-Cholinergic Effect in Isolated Small Intestine of Rat The test on gastric juice secretion inhibiting activity in gastric mucosa was conducted in accordance with the method of C. A. M. Hogben (American Journal of Physiology, vol. 180, page 641 (1955)). As a result it was confirmed that the administration of typical compounds of this invention, that is, n-butyl-tri-(fi-propyloxyethyl) ammonium iodide and p-methoxybenzyl-tri-(B-propyloxyethyl) ammonium bromide, each in an amount of 500 inhibited the gastric juice secretion in gastric mucosa of a frog administered with 10 of tetragastrin. In the pharmacological test using isolated small intestines of rats, administration of the above two compounds of this invention, each in an amount of 100 did not exhibit any anti-cholinergic effect against the administration of 1 of acetylcholine.

It is known that anti-cholinergic substances heretofore used as anti-ulcer agents have side-effects such as constipation and dryness of mouth. Accordingly, it will be readily understood that the compounds of this invention are effective and useful as anti-ulcer agents, Acute T 0xicity (Male DD mice having a body weight of 19:2 g.). p-Phenoxybenzyl-tri-(fl-propyloxyethyl) ammonium bromide:

LD (p.o.) -840 mg./kg. (1344-600 mg./kg.) LD (i.p.)=l9 mg./kg. (20.8-17.3 mg./kg.) Z-Naphthylmethyl-tri-(B-propyloxyethyl) ammonium bromide:

LD (p.o.)=515 mg./kg. (609-430 mg./kg.) LD (i.p.)=38 mg./kg. (46.7-30.8 mg./kg.)

Novel tri-(p-propyloxyethyl) amine quaternary salts of this invention may be prepared by reacting tri-(B-propyloxyethyl) amine of the above formula (II) with at least an equivalent amount of a halogen compound of the above formula (III) in an inert solvent at a temperature ranging from room temperature to the reflux temperature of the reaction mixture. As inert solvents, acetone and lower alcohols such as ethyl alcohol are preferable. After the completion of the reaction, the desired product may be isolated by conventional methods such as removal of solvent by distillation.

The process of the synthesis of compounds of this invention will now be detailed by referring to Examples.

EXAMPLE 1 Synthesis of cinnamyl-tri-(p-propyloxyethyl) ammonium bromide To a solution of 20 g. of tri-(fl-propyloxyethyl) amine in ml. of ethyl alcohol was added 14.3 g. of cinnamyl bromide, and the mixture was refluxed for 3 hours. Then ethyl alcohol was distilled off, and the residue was washed with diethyl ether to obtain 13.5 g. of crude crystals.

Efl'cets of Compound A and Compound B on amount, pH, HCl concentration and pepsin activity of gastric juice in pylorus ligated rats Num- Volume of Pepsin activity From the results shown in the above Tables 1 and 2, it is seen that the Compound A (para-phenoxybenzyl-tri- (fi-propyloxyethyl) ammonium bromide) has an excellent anti-ulcer activity over the Compound B, while the former Compound A imposes hardly any influences on the pH, hydrochloric acid concentration and pepsin activity of gastric juice.

The crude crystals were recrystallized from ethyl acetate to obtain 11.5 g. of cinnamyl-tri-(fl-propyloxyethyl) ammonium bromide melting at 119120 C. The yield was 33%. The results of the elementary analysis of the product as C H O NBr are as follows:

Calculated: C=61.00, H=8.96, N=2.96. Found: C=61.03, H=9.03, N=3.09.

5 EXAMPLE 2 was recrystallized from ethylalcohol ethyl acetate to obtain 27 g. of p-phenoxybenzyl-tri-(fl-propyloxyethyl) ammonium bromide. The yield of the product was 46% and the product had a melting point of 133.4 C. The results of the elementary analysis of the product as C H 0 NBr are as follows:

Calculated: C=62.44, H=8.23, N=2.60. Found: C: 62.43, H=8.19, N=2.51.

EXAMPLES 4-19 Tris-(fi-propyloxyethyl) amine of the above formula (II) was reacted with various compounds of the above formula (III) in the same manner as described in Example 1. Resulting compounds are shown in Table 3.

Value of elementary analysis I Molecular Calculated/Found Meltintg pom Example R X Formula Weight 0 H N 0.

4 cH,- cr'r.)2- I I 018114003191 445.44 4852/4873 9.05/8.95 215/389 86-87 :5 (m 0H2)? I C14H4203NI 459.47 4955/4998 921/935 305/220 115-117 5.; (3H3-(C'Hz)i I 028114405191 473.50 5073/5057 937/935 295/285 145 7 CH8-(CH2)5 I ozlHiroaNl 487.52 51.74/5L85 951/953 287/294 148 CH3(CH2)4' I CzzHraOaNI 501.55 5258/5280 955/954 279/259 133 9 I CHHNOQNI 499.53 52.89/52.72 9.281958 280/312 105-100 GHQ- 10 I CuHQOrNI 507.50 5443/5442 834/829 270/288 115 CHQCHP 11 Br CZZHQQOINBX' 474.49 5822/5830 8.50/8.42 295/275 133 CO-CH2- 12 I I C23H zO NI 523.50 5277/5270 8.09/7.97 258/290 78 O-OHZCHr-- 13..-:.:.= Br C23H1204NBI 475.51 57.97/57.85 8.89/8.85 29413.07 97 CHsO- CH:

14. Br CMHHOANBI 490.537 58.76/58.78 9.04/8.92 285/292 99-100 CzHsO CH:

15. Br C25HA0O4NB1' 504.57 5951/5940 919/213 277/290 92-93 CsH10 CH3- 10 Br C2H48O4NB1 518.59 5022/5019 933/924 270/277 97-98 C4H00- CHI- 17..-..:.. Br cflHfllolNBl 552.5 53.03/5290 859/832 253/255 110-111 CH2O- -CH2- 18.......= 3H2- Br C2oH12O3NBr 495.55 6289/5200 853/812 282/310 90 19.......== CH5 Br CflHflOSNBI 474.53 8074/0035 93519.11 295/300 119 results of the elementary analysis of the product as C H' O NBr are as follows:

Calculated: C=62.89, H=8.53,

C=62.84, H=8.54, N=2.90.

EXAMPLE 3 Synthesis of p-phenoxybenzyl-tri-(B-propyloxyethyl) ammonium bromide To a solution of g. of tri-(B-propyloxyethyl) amine in 180 ml. of ethyl alcohol was added 20 g. of p-phenoxybenzyl bromide, and the mixture was refiuxed'for 3 hours. Then the ethyl alcohol was distilled off, and residue was washed with diethyl ether. The resulting crude crystal N=2.82. Found:

7 EXAMPLE 20 Preparation of suspension for subcutaneous injection G. p-Phenoxybenzyl-tri-(fi-propyloxyethyl) ammonium bromide 50.0 Tween 80 10.0 C.M.C.-Na 10.0 Distilled water to 1.0 1.

EXAMPLE 21 Preparation of tablets p-Phenoxybenzyl-tri-(fi propyloxyethyl)ammonium bromide 50.0 Lactose 58.5 Microcrystalline cellulose 35.0 Hydroxypropyl starch 25.0 Magnesium stearate 1.5

p-Phenoxybenzyl-tri-(p propyloxyethyl) ammonium bromide, lactose, microcrystalline cellulose, hydroxypropyl starch and magnesium stearate were blended well to obtain a homogeneous mixture. The mixture was compressed into tablets, each weighing 170 mg., with the use of a flat punch of 8 mm. diameter. Each tablet contains mg. of the compound of this invention.

EXAMPLE 22 Preparation of capsules Z-Naphtylmethyl tri (fl-propyloxyethyl) ammonium bromide 50.0 Lactose 218.5 Calcium stearate 1.5

2-Naphtylmethyl tri (fl-propyloxyethyl) ammonium bromide, lactose and calcium stearate were blended well to form a homogeneous mixture. The resulting mixture was filled into 1000 gelatin capsules. Each capsule contains 50 mg. of the compound of this invention.

What is "claimed is:

1. Para-phenoxybenzyl-tri-(fl propyloxyethyl) ammonium bromide.

References Cited UNITED STATES PATENTS 3,372,194 3/1968 Arnkjael' et al. 260567.6M

FOREIGN PATENTS 1,025,160 4/1966 Great Britain.

LEON ZITVER, Primary Examiner D. B. SPRINGER, Assistant Examiner us. c 1. X.R. 424-316 

